Skip to main content

Table 1 Patients Characteristics (n = 95).

From: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial

Age (yrs)

 

   Median

59

   Range

18-80

Sex (No)

 

   Male

56

   Female

39

ECOG (No)

 

   Grade 0

36

   Grade 1

40

   Grade 2

17

   Grade 3

2

Time since initial diagnosis (days)

 

   Median

180

   Range

0-6141

Disease Status (%)

 

   Recurrence/Progression

62

Site of tumor (%)

 

   Stomach

33

   Liver

28

   Small intestine

23

   Peritoneum

5

   Rectum

5

   Colon

4

   Esophagus

1

   Pancreas

1